K. Hirth
Chairman bij IO BIOTECH, INC.
Vermogen: 271 827 $ op 31-03-2024
Oorsprong van het eerstegraads netwerk van K. Hirth
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 31 | |
| Public Company | Biotechnology | 22 | |
| Public Company | Pharmaceuticals: Major | 18 | |
12
| Private Company | Miscellaneous Commercial Services | 12 |
Plexxikon, Inc.
 Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA.
12
| Subsidiary | Miscellaneous Commercial Services | 12 |
Escient Pharmaceuticals, Inc.
 Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA.
10
| Holding Company | Biotechnology | 10 |
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France.
10
| Holding Company | Pharmaceuticals: Major | 10 |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark.
9
| Subsidiary | Biotechnology | 9 |
Iconic Therapeutics, Inc.
 Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA.
8
| Subsidiary | Biotechnology | 8 |
Afferent Pharmaceuticals, Inc.
 Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
TRex Bio Ltd.
 TRex Bio Ltd. BiotechnologyHealth Technology TRex Bio Ltd. is a British company that provides biotechnology research and development services. The private company is based in London, UK. The company was founded in 2018 by Houman Ashrafian.
3
| Private Company | Biotechnology | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met K. Hirth via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| ABBOTT LABORATORIES | Medical Specialties | General Counsel Corporate Officer/Principal Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Treasurer Corporate Officer/Principal Corporate Officer/Principal | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Investor Relations Contact Corporate Officer/Principal | |
| INTERMUNE INC | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal General Counsel | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| STANDARD BIOTOOLS INC. | Medical Specialties | Corporate Officer/Principal Chairman | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal General Counsel | |
| CODEXIS, INC. | Chemicals: Specialty | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Chairman Corporate Officer/Principal Director/Board Member | |
| SUTRO BIOPHARMA, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal Private Equity Investor Private Equity Investor Private Equity Investor | |
| GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| Dartmouth College | College/University | Undergraduate Degree Masters Business Admin Undergraduate Degree | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) MiscellaneousMiscellaneous Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Miscellaneous | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
| Yale University | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| Tufts University | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree Undergraduate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
| University of California San Diego | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree Undergraduate Degree | |
| The University of California, San Francisco | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree Graduate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree Graduate Degree Corporate Officer/Principal Graduate Degree | |
7TM A/S
 7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Pharmaceuticals: Major | Founder Founder | |
Juvaris BioTherapeutics, Inc.
 Juvaris BioTherapeutics, Inc. BiotechnologyHealth Technology Juvaris BioTherapeutics, Inc. develops novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. The company was founded by Martin D. Cleary, Jeff Fairman and Steven W. Dow in February 2003 and is headquartered in Burlingame, CA. | Biotechnology | Director/Board Member Chief Executive Officer Founder | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Harvard Medical School | College/University | Graduate Degree Corporate Officer/Principal | |
Astex Pharmaceuticals, Inc.
 Astex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded on May 28, 1997 and is headquartered in Pleasanton, CA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Acesion Pharma ApS
 Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Novo Ventures (US), Inc.
 Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Investment Managers | Private Equity Investor Corporate Officer/Principal Private Equity Investor | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Undergraduate Degree | |
| Harvard Business School | College/University | Graduate Degree Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Chairman Director/Board Member | |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Director/Board Member Director/Board Member | |
HepaRegeniX GmbH
 HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Artizan Biosciences, Inc.
 Artizan Biosciences, Inc. Medical/Nursing ServicesHealth Services Artizan Biosciences, Inc. engages in the provision of healthcare services. It develops curative treatments for inflammatory diseases. The company was founded by Richard A. Flavell, Noah W. Palm and Marcel R. de Zoete and is headquartered in New Haven, CT. | Medical/Nursing Services | Director/Board Member Chief Executive Officer | |
AFYX Therapeutics AS
 AFYX Therapeutics AS Miscellaneous Commercial ServicesCommercial Services AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Financial Conglomerates | Chief Investment Officer Corporate Officer/Principal | |
| ENTRADA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| PASSAGE BIO, INC. | Biotechnology | Director/Board Member Director/Board Member Comptroller/Controller/Auditor | |
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 34 |
| Denemarken | 14 |
| Verenigd Koninkrijk | 2 |
| Ierland | 2 |
| Finland | 2 |
Sectoraal
| Health Technology | 28 |
| Consumer Services | 12 |
| Finance | 6 |
| Commercial Services | 5 |
| Process Industries | 2 |
Operationeel
| Director/Board Member | 632 |
| Corporate Officer/Principal | 266 |
| Independent Dir/Board Member | 162 |
| Chairman | 85 |
| Chief Executive Officer | 83 |
Sterkste connecties
| Insiders | |
|---|---|
| Michael Ross | 44 |
| Heath Lukatch | 43 |
| Patrick Heron | 42 |
| Claus Asbjørn Andersson | 41 |
| Patrick Enright | 41 |
| Todd Foley | 38 |
| Jack Nielsen | 38 |
| Kurt von Emster | 34 |
| Georges Gemayel | 33 |
| James Manuso | 29 |
| Stephan Christgau | 29 |
| Charles Casamento | 27 |
| William Greene | 26 |
| Carole Nüchterlein | 26 |
| Jim Scopa | 26 |
